Wedbush Expects Stronger Earnings for Artiva Biotherapeutics

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Investment analysts at Wedbush increased their FY2025 earnings estimates for shares of Artiva Biotherapeutics in a report released on Wednesday, November 12th. Wedbush analyst M. Fan now expects that the company will earn ($3.49) per share for the year, up from their prior forecast of ($3.55). Wedbush has a “Outperform” rating and a $23.00 price objective on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. Wedbush also issued estimates for Artiva Biotherapeutics’ Q4 2025 earnings at ($0.90) EPS, Q1 2026 earnings at ($0.94) EPS, Q2 2026 earnings at ($0.65) EPS, Q3 2026 earnings at ($0.65) EPS, Q4 2026 earnings at ($0.72) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.96) EPS, FY2028 earnings at ($3.39) EPS and FY2029 earnings at ($3.02) EPS.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04.

Several other equities research analysts have also issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a report on Friday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Thursday, October 30th. Finally, HC Wainwright boosted their target price on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Artiva Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ ARTV opened at $3.89 on Monday. The business’s 50-day moving average price is $3.40 and its two-hundred day moving average price is $2.71. Artiva Biotherapeutics has a one year low of $1.47 and a one year high of $13.19. The company has a market capitalization of $95.50 million, a P/E ratio of -1.51 and a beta of 3.06.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Ground Swell Capital LLC acquired a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $38,000. Prelude Capital Management LLC bought a new stake in Artiva Biotherapeutics during the 3rd quarter valued at approximately $41,000. Bank of America Corp DE boosted its stake in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Artiva Biotherapeutics in the 2nd quarter valued at approximately $48,000. Finally, Bridgeway Capital Management LLC bought a new position in Artiva Biotherapeutics in the 2nd quarter worth approximately $53,000.

Insider Activity

In related news, CEO Fred Aslan sold 25,500 shares of the company’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $6.00, for a total transaction of $153,000.00. Following the completion of the sale, the chief executive officer directly owned 356,721 shares of the company’s stock, valued at approximately $2,140,326. This represents a 6.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 21.40% of the company’s stock.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.